Alzamend Neuro Stock Forum

$Alzamend Neuro (ALZN.US)$ i just entered yesterday after watching on youtube analyst t BWB & its going up👍

$Alzamend Neuro (ALZN.US)$
Can This New Lithium Formulation Revolutionize Bipolar Disorder Treatment? Alzamend's Phase II Trial Targets 7M+ Patients

$Alzamend Neuro (ALZN.US)$
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital
Tuesday, 4th March at 8:10 am
ATLANTA, March 04, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (NASDAQ: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorde...

$Alzamend Neuro (ALZN.US)$
Can Alzamend's New Lithium Formulation Eliminate Monitoring Requirements? Phase II Trial Set for 2025

$Alzamend Neuro (ALZN.US)$
EXCLUSIVE: Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 2025
Benzinga· 1 min ago
Alzamend Neuro(ALZN.US)
On Tuesday, Alzamend Neuro, Inc. (NASDAQ:ALZN) announced its plans to initiate the first of five phase 2 clinical studies of AL001. The first study, in healthy human subjects, is expected to commence in the second quarter of 2025.
The study follows the development of a novel head coil by Tesla Dynamic Coils BV, a key component of the clinical...

$Alzamend Neuro (ALZN.US)$ Trash

$Alzamend Neuro (ALZN.US)$ EXCLUSIVE: Alzamend Tells Benzinga 'Head-to-head Studies of AL001 Versus a Marketed Lithium Carbonate Product Will Be Conducted for Comparisons of Lithium Blood and Brain/brain-structure Pharmacokinetics in Healthy, Alzheimer's Disease, BD, MDD, and PTSD'
Benzinga· 1 min ago
On Wednesday, Alzamend Neuro, Inc. (NASDAQ:ALZN) announced it had completed the head coil by Tesla Dynamic Coils BV.
The development of the head coil was necessary to facilitate Alzamend's fiv...

$Alzamend Neuro (ALZN.US)$
Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs
Thursday, 12th December at 8:00 am
• During the six months ended October 31, 2024, net cash provided by financing activities was $8.3 million
• Stockholder equity of $3.8 million at October 31, 2024, including $4.1 million of cash
• Strengthened balance sheet in preparation for five clinical trials to be initiated in 2025
Alzamend Neuro, Inc. (NASDAQ: ALZN) ("...

$Alzamend Neuro (ALZN.US)$ this grabge should move its horrible

$Alzamend Neuro (ALZN.US)$ Alzamend Neuro Tells Benzinga 'Data Confirm the Positive Topline Results Announced in June 2023 Identifying a Maximum Tolerated Dose as Assessed by an Independent Safety Review Committee'!
Alzamend Neuro Tells Benzinga 'Identified Dose Is Unlikely to Require Lithium Therapeutic Drug Monitoring'